Why Novavax, Inc Is Tanking Today
After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.
Here's a review of the key highlights from the company's big announcement:
First, Novavax said that its phase 3 Prepare trial -- which is studying its respiratory syncytial virus candidate, RSV F Vaccine, in infants via maternal immunization -- continues to progress. The company said that it is actively enrolling patients at 80 sites in 11 countries.
Source: Fool.com
Novavax Inc. Aktie
6,75 €
0,45 %
Die Community bevorzugt leicht Novavax Inc. mit mehr Buy- als Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Novavax Inc. mit einem Kursziel von 11 € im Vergleich zum aktuellen Kurs von 6.75 € zu erwarten.
